Table 2.
The mean SCE in human lymphocytes treated with Sp alone or with Sp+MMC in the absence of S9mix
| Test substance | Treatment time (h) | Concentrations (μL/mL) | Min–max SCE | SCE/cell ± SE |
|---|---|---|---|---|
| Control | – | – | 1–16 | 5.84 ± 0.72 |
| Methanol | 24 | 6.0 | 2–16 | 6.46 ± 0.70 |
| MMC | 24 | 0.2 μg/mL | 13–64 | 43.29 ± 1.79 |
| Sp | 24 | 1.5 | 1–12 | 5.48 ± 0.48 |
| 24 | 3.0 | 1–13 | 5.96 ± 0.12 | |
| 24 | 6.0 | 2–14 | 7.06 ± 0.02 a2b1 | |
| Sp+MMC | 24 | 1.5 Sp+MMC* | 21–65 | 39.29 ± 1.66 a1b1 |
| 24 | 3.0 Sp+MMC* | 16–64 | 41.09 ± 1.69 a1b1 | |
| 24 | 6.0 Sp+MMC* | 1–63 | 41.00 ± 2.52 a1b1 | |
| Methanol | 48 | 6.0 | 1–15 | 5.62 ± 0.14 |
| MMC | 48 | 0.2 μg/mL | 53–121 | 92.88 ± 2.32 |
| Sp | 48 | 1.5 | 2–17 | 7.24 ± 0.24 |
| 48 | 3.0 | 1–20 | 8.46 ± 0.22 a1b1 | |
| 48 | 6.0 | 2–22 | 9.68 ± 0.32 a1b1 | |
| Sp+MMC | 48 | 1.5 Sp+MMC* | 60–127 | 98.80 ± 2.36 a1b1 |
| 48 | 3.0 Sp+MMC* | 52–133 | 75.42 ± 3.34 a1b1 | |
| 48 | 6.0 Sp+MMC* | – | 0.0 ± 0.0+ |
a: significant from control; b: significant from methanol control; c: significant from positive control, MMC; a1b1: P < 0.05; a2b2: P < 0.01
* MMC (Mitomycin C): 0.2 μg/mL
+Not scorable for excessive toxicity